1. Natsuizaka, M. et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Resp Crit Care 190, 773–779 (2014).
2. Desai, T. J., Brownfield, D. G. & Krasnow, M. A. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 507, 190–194 (2014).
3. Rock, J. R. et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc National Acad Sci 108, E1475–E1483 (2011).
4. Selman, M. et al. Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy. Ann Intern Med 134, 136 (2001).
5. Kropski, J. A. et al. Extensive Phenotyping of Individuals at Risk for Familial Interstitial Pneumonia Reveals Clues to the Pathogenesis of Interstitial Lung Disease. Am J Resp Crit Care 191, 417–426 (2015).
6. Alder, J. K. et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc National Acad Sci 105, 13051–13056 (2008).
7. Liang, J. et al. Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice. Nat Med 22, 1285–1293 (2016).
8. Königshoff, M. et al. WNT1-inducible signaling protein–1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 119, 772–787 (2009).
9. Stewart, G. A. et al. Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up‐regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes. J Pathology 199, 488–495 (2003).
10. Horowitz1, J. & Thannickal1, V. Epithelial-Mesenchymal Interactions in Pulmonary Fibrosis. Semin Respir Crit Care Med 27, 600–612 (2006).
11. Liu, F. et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biology 190, 693–706 (2010).
12. Booth, A. J. et al. Acellular Normal and Fibrotic Human Lung Matrices as a Culture System for In Vitro Investigation. Am J Resp Crit Care 186, 866–876 (2012).
13. Chen, H. et al. Mechanosensing by the α6-integrin confers an invasive fibroblast phenotype and mediates lung fibrosis. Nat Commun 7, 12564 (2016).
14. Tschumperlin, D. J. Matrix, Mesenchyme, and Mechanotransduction. Ann Am Thorac Soc 12, S24–S29 (2015).
15. Zhou, Y. et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 123, 1096–1108 (2013).
16. Wipff, P.-J., Rifkin, D. B., Meister, J.-J. & Hinz, B. Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix. J Cell Biology 179, 1311– 1323 (2007).
17. Huang, X. et al. Matrix Stiffness–Induced Myofibroblast Differentiation Is Mediated by Intrinsic Mechanotransduction. Am J Resp Cell Mol 47, 340–348 (2012).
18. Vancheri, C., Failla, M., Crimi, N. & Raghu, G. Idiopathic pulmonary fibrosis: A disease with similarities and links to cancer biology. Eur Respir J 35, 496–504 (2010).
19. Karampitsakos, T. et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 45, 1–10 (2017).
20. OZAWA, Y. et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 14, 723–728 (2009).
21. Goto, T., Maeshima, A., Akanabe, K., Oyamada, Y. & Kato, R. Acute Exacerbation of Idiopathic Pulmonary Fibrosis of Microscopic Usual Interstitial Pneumonia Pattern after Lung Cancer Surgery. Ann Thorac Cardiovas 17, 573–576 (2011).
22. Goto, T., Maeshima, A., Oyamada, Y. & Kato, R. Idiopathic pulmonary fibrosis as a prognostic factor in non-small cell lung cancer. Int J Clin Oncol 19, 266–273 (2014).
23. Goto, T. Measuring Surgery Outcomes of Lung Cancer Patients with Concomitant Pulmonary Fibrosis: A Review of the Literature. Cancers 10, 223 (2018).
24. Hendriks, L. E. L., Drent, M., Haren, E. H. J. van, Verschakelen, J. A. & Verleden, G. M. Lung cancer in idiopathic pulmonary fibrosis patients diagnosed during or after lung transplantation. Respir Medicine Case Reports 5, 37–39 (2012).
25. Daniels, C. E. & Jett, J. R. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 11, 431–437 (2005).
26. Horowitz, J. C., Osterholzer, J. J., Marazioti, A. & Stathopoulos, G. T. “Scar- cinoma”: Viewing the fibrotic lung mesenchymal cell in the context of cancer biology. Eur Respir J 47, 1842–1854 (2016).
27. Iwata, T. et al. Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis. Ann Thorac Surg 102, 1905–1910 (2016).
28. Iwata, T. et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today 45, 1263–1270 (2015).
29. Costabel, U. et al. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration 94, 408–415 (2017).
30. Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New Engl J Medicine 370, 2071–2082 (2014).
31. Zuo, F. et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc National Acad Sci 99, 6292–6297 (2002).
32. Yang, I. V. et al. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 68, 1114–1121 (2013).
33. Kass, D. J. & Kaminski, N. Evolving Genomic Approaches to Idiopathic Pulmonary Fibrosis: Moving Beyond Genes. Clin Transl Sci 4, 372–379 (2011).
34. Baumgartner, K. B., Samet, J. M., Stidley, C. A., Colby, T. V. & Waldron, J. A. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Resp Crit Care 155, 242–248 (2012).
35. Yang, I. V. & Schwartz, D. A. Epigenetics of idiopathic pulmonary fibrosis. Transl Res 165, 48–60 (2015).
36. Coward, W. R., Watts, K., Feghali-Bostwick, C. A., Knox, A. & Pang, L. Defective Histone Acetylation Is Responsible for the Diminished Expression of Cyclooxygenase 2 in Idiopathic Pulmonary Fibrosis▿ †‡. Mol Cell Biol 29, 4325–4339 (2009).
37. Coward, W. R., Watts, K., Feghali-Bostwick, C. A., Jenkins, G. & Pang, L. Repression of IP-10 by Interactions between Histone Deacetylation and Hypermethylation in Idiopathic Pulmonary Fibrosis▿ †. Mol Cell Biol 30, 2874–2886 (2010).
38. Sanders, Y. Y., Tollefsbol, T. O., Varisco, B. M. & Hagood, J. S. Epigenetic Regulation of Thy-1 by Histone Deacetylase Inhibitor in Rat Lung Fibroblasts. Am J Resp Cell Mol 45, 16–23 (2011).
39. Cisneros, J. et al. Hypermethylation-mediated silencing of p14ARF in fibroblasts from idiopathic pulmonary fibrosis. Am J Physiol-lung C 303, L295–L303 (2012).
40. Hu, B., Gharaee-Kermani, M., Wu, Z. & Phan, S. H. Epigenetic Regulation of Myofibroblast Differentiation by DNA Methylation. Am J Pathology 177, 21–28 (2010).
41. Hu, B., Gharaee-Kermani, M., Wu, Z. & Phan, S. H. Essential Role of MeCP2 in the Regulation of Myofibroblast Differentiation during Pulmonary Fibrosis. Am J Pathology 178, 1500–1508 (2011).
42. Rabinovich, E. I. et al. Global methylation patterns in idiopathic pulmonary fibrosis. Plos One 7, (2012).
43. Sanders, Y. Y. et al. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Resp Crit Care 186, 525–535 (2012).
44. Yang, I. V. et al. Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. Am J Resp Crit Care 190, 1263–1272 (2014).
45. Yang, I. V. & Schwartz, D. A. Epigenetic control of gene expression in the lung. Am J Resp Crit Care 183, 1295–1301 (2011).
46. King, T. E., Pardo, A. & Selman, M. Idiopathic pulmonary fibrosis. Lancet 378, 1949–1961 (2011).
47. Ordway, J. M. et al. Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets. Carcinogenesis 27, 2409–2423 (2006).
48. Yang, I. V. & Schwartz, D. A. Epigenetics of idiopathic pulmonary fibrosis. Transl Res 165, 48–60 (2015).
49. Rodriques, S. G. et al. Slide-seq: A scalable technology for measuring genome- wide expression at high spatial resolution. Science 363, 1463–1467 (2019).
50. Fernández-Medarde, A. & Santos, E. The RasGrf family of mammalian guanine nucleotide exchange factors. Biochimica Et Biophysica Acta Bba - Rev Cancer 1815, 170–188 (2011).
51. Tatsumoto, T., Xie, X., Blumenthal, R., Okamoto, I. & Miki, T. Human Ect2 Is an Exchange Factor for Rho Gtpases, Phosphorylated in G2/M Phases, and Involved in Cytokinesis. J Cell Biology 147, 921–928 (1999).
52. Fam, N. P. et al. Cloning and Characterization of Ras-GRF2, a Novel Guanine Nucleotide Exchange Factor for Ras Downloaded from. MOLECULAR AND CELLULAR BIOLOGY 17, 1396–1406 (1997).
53. Ma, X. et al. βArrestin1 regulates the guanine nucleotide exchange factor RasGRF2 expression and the small GTPase rac-mediated formation of membrane protrusion and cell motility. J Biol Chem 289, 13638–13650 (2014).
54. Li, S., Tian, X., Hartley, D. M. & Feig, L. A. Distinct roles for Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and Ras-GRF2 in the induction of long- term potentiation and long-term depression. J Neurosci 26, 1721–1729 (2006).
55. Ruiz, S., Santos, E. & Bustelo, X. R. The use of knockout mice reveals a synergistic role of the vav1 and rasgrf2 gene deficiencies in lymphomagenesis and metastasis. Plos One 4, (2009).
56. Calvo, F. et al. RasGRF suppresses Cdc42-mediated tumour cell movement, cytoskeletal dynamics and transformation. Nat Cell Biol 13, 819–826 (2011).
57. Chen, H. et al. Aberrant methylation of RASGRF2 and RASSF1A in human non- small cell lung cancer. Oncol Rep 15, (2006).
58. Hagihara, A. et al. Identification of 27 5′ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 23, 8705–8710 (2004).
59. Jacinto, F. V., Ballestar, E., Ropero, S. & Esteller, M. Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. Cancer Res 67, (2007).
60. Qiu, C., Yu, M., Shan, L. & Snyderwine, E. G. Allelic imbalance and altered expression of genes in chromosome 2q11–2q16 from rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Oncogene 22, 1253–1260 (2003).
61. Lu, P. et al. RasGRF2 promotes migration and invasion of colorectal cancer cells by modulating expression of MMP9 through Src/Akt/NF-κB pathway. Cancer Biol Ther 20, 435–443 (2019).
62. Baschieri, F. et al. Spatial control of Cdc42 signalling by a GM130-RasGRF complex regulates polarity and tumorigenesis. Nat Commun 5, (2014).
63. Kosibaty, Z. et al. Cytoplasmic expression of epithelial cell transforming sequence 2 in lung adenocarcinoma and its implications for malignant progression. Lab Invest 99, 551–567 (2019).
64. Saito, S. et al. Deregulation and Mislocalization of the Cytokinesis Regulator ECT2 Activate the Rho Signaling Pathways Leading to Malignant Transformation. J Biol Chem 279, 7169–7179 (2004).
65. Detre, S., Jotti, G. S. & Dowsett, M. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. Clin Pathol 48, 876–879 (1995).
66. Murata, Y. et al. ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma. Cancer Sci 105, 490–497 (2014).